En studie for å teste langtidsbehandlingen av bimekizumab hos studiedeltakere med moderat til alvorlig Hidradenitis Suppurativa (BE HEARD EXT)
En fase 3, åpen etikett, parallell gruppe, multisenter, utvidelsesstudie som evaluerer langtidsbehandlingen av bimekizumab hos studiedeltakere med moderat til alvorlig Hidradenitis Suppurativa
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Campbelltown, Australia
- Hs0005 30015
-
Carlton, Australia
- Hs0005 30016
-
East Melbourne, Australia
- Hs0005 30011
-
Kogarah, Australia
- Hs0005 30017
-
Parkville, Australia
- Hs0005 30018
-
St Leonards, Australia
- Hs0005 30014
-
Westmead, Australia
- Hs0005 30009
-
Woolloongabba, Australia
- Hs0005 30012
-
-
-
-
-
Leuven, Belgia
- Hs0005 40002
-
Woluwe-Saint-Lambert, Belgia
- Hs0005 40121
-
-
-
-
-
Pleven, Bulgaria
- Hs0005 40313
-
Sofia, Bulgaria
- Hs0005 40284
-
Sofia, Bulgaria
- Hs0005 40311
-
Sofia, Bulgaria
- Hs0005 40314
-
Sofia, Bulgaria
- Hs0005 40315
-
Stara Zagora, Bulgaria
- Hs0005 40353
-
-
-
-
-
Barrie, Canada
- Hs0005 50233
-
Cobourg, Canada
- Hs0005 50172
-
Edmonton, Canada
- Hs0005 50135
-
London, Canada
- Hs0005 50174
-
Richmond Hill, Canada
- Hs0005 50190
-
Saskatoon, Canada
- Hs0005 50192
-
Surrey, Canada
- Hs0005 50133
-
Waterloo, Canada
- Hs0005 50134
-
Winnipeg, Canada
- Hs0005 50136
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35249
- Hs0005 50140
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85006
- Hs0005 50175
-
-
California
-
Fountain Valley, California, Forente stater, 92708
- Hs0005 50162
-
Los Angeles, California, Forente stater, 90045
- Hs0005 50161
-
San Diego, California, Forente stater, 92123
- Hs0005 50220
-
Thousand Oaks, California, Forente stater, 91320
- Hs0005 50196
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- Hs0005 50199
-
North Miami Beach, Florida, Forente stater, 33162-4708
- Hs0005 50205
-
Orange Park, Florida, Forente stater, 32073
- Hs0005 50152
-
Pembroke Pines, Florida, Forente stater, 33028
- Hs0005 50184
-
-
Georgia
-
Sandy Springs, Georgia, Forente stater, 30329
- Hs0005 50193
-
Watkinsville, Georgia, Forente stater, 30677
- Hs0005 50280
-
-
Indiana
-
Plainfield, Indiana, Forente stater, 46168
- Hs0005 50234
-
-
Kentucky
-
Murray, Kentucky, Forente stater, 42071
- Hs0005 50425
-
-
Massachusetts
-
Beverly, Massachusetts, Forente stater, 01915
- Hs0005 50198
-
Boston, Massachusetts, Forente stater, 02215
- Hs0005 50146
-
-
Michigan
-
Clarkston, Michigan, Forente stater, 48346
- Hs0005 50178
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Hs0005 50105
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68144
- Hs0005 50194
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89148
- Hs0005 50208
-
-
New Hampshire
-
Newington, New Hampshire, Forente stater, 03801
- Hs0005 50159
-
-
New Jersey
-
East Windsor, New Jersey, Forente stater, 08520
- Hs0005 50137
-
Verona, New Jersey, Forente stater, 07044
- Hs0005 50200
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87102
- Hs0005 50237
-
-
New York
-
New York, New York, Forente stater, 10003
- Hs0005 50235
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27516
- Hs0005 50151
-
Durham, North Carolina, Forente stater, 27710
- Hs0005 50211
-
Winston-Salem, North Carolina, Forente stater, 27157
- Hs0005 50179
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45219
- Hs0005 50177
-
Columbus, Ohio, Forente stater, 43213
- Hs0005 50138
-
Columbus, Ohio, Forente stater, 43230
- Hs0005 50145
-
Fairborn, Ohio, Forente stater, 45324
- Hs0005 50202
-
-
Oklahoma
-
Tulsa, Oklahoma, Forente stater, 74137
- Hs0005 50204
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forente stater, 17033
- Hs0005 50147
-
-
Rhode Island
-
Johnston, Rhode Island, Forente stater, 02919
- Hs0005 50008
-
Providence, Rhode Island, Forente stater, 02903
- Hs0005 50180
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Hs0005 50084
-
Greenville, South Carolina, Forente stater, 29615
- Hs0005 50236
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37215
- Hs0005 50142
-
-
Texas
-
Arlington, Texas, Forente stater, 76011
- Hs0005 50201
-
Pflugerville, Texas, Forente stater, 78660
- Hs0005 50148
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84107
- Hs0005 50141
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Hs0005 50270
-
-
-
-
-
Amiens, Frankrike
- Hs0005 40197
-
Antony, Frankrike
- Hs0005 40245
-
Auxerre, Frankrike
- Hs0005 40321
-
La Rochelle, Frankrike
- Hs0005 40320
-
Le Mans, Frankrike
- Hs0005 40355
-
Lyon, Frankrike
- Hs0005 40247
-
Marseille, Frankrike
- Hs0005 40130
-
Nice, Frankrike
- Hs0005 40132
-
Reims, Frankrike
- Hs0005 40404
-
Rouen, Frankrike
- Hs0005 40318
-
Saint-Etienne, Frankrike
- Hs0005 40403
-
Saint-Mandé, Frankrike
- Hs0005 40246
-
Toulon, Frankrike
- Hs0005 40285
-
Toulouse, Frankrike
- Hs0005 40286
-
-
-
-
-
Athens, Hellas
- Hs0005 40251
-
Efkarpia, Hellas
- Hs0005 40252
-
-
-
-
-
Dublin, Irland
- Hs0005 40344
-
-
-
-
-
Catania, Italia
- Hs0005 40261
-
Roma, Italia
- Hs0005 40263
-
Rozzano, Italia
- Hs0005 40258
-
Torino, Italia
- Hs0005 40330
-
-
-
-
-
Bunkyō City, Japan
- Hs0005 20196
-
Fukuoka, Japan
- Hs0005 20144
-
Kagoshima, Japan
- Hs0005 20195
-
Kurume, Japan
- Hs0005 20170
-
Kyoto, Japan
- Hs0005 20190
-
Nagoya, Japan
- Hs0005 20033
-
Nakagami-gun, Japan
- Hs0005 20152
-
Nishinomiya, Japan
- Hs0005 20178
-
Obihiro, Japan
- Hs0005 20153
-
Osaka, Japan
- Hs0005 20037
-
Sapporo, Japan
- Hs0005 20154
-
Sendai, Japan
- Hs0005 20171
-
tabashi City, Japan
- Hs0005 20043
-
-
-
-
-
Breda, Nederland
- Hs0005 40351
-
Groningen, Nederland
- Hs0005 40292
-
Rotterdam, Nederland
- Hs0005 40264
-
-
-
-
-
Lodz, Polen
- Hs0005 40347
-
Rzeszów, Polen
- Hs0005 40293
-
Warsaw, Polen
- Hs0005 40335
-
Wroclaw, Polen
- Hs0005 40095
-
Wroclaw, Polen
- Hs0005 40333
-
Wroclaw, Polen
- Hs0005 40334
-
-
-
-
-
Badalona, Spania
- Hs0005 40266
-
Barcelona, Spania
- Hs0005 40159
-
Barcelona, Spania
- Hs0005 40267
-
Granada, Spania
- Hs0005 40298
-
Las Palmas de Gran Canaria, Spania
- Hs0005 40294
-
Madrid, Spania
- Hs0005 40268
-
Manises, Spania
- Hs0005 40297
-
Pontevedra, Spania
- Hs0005 40295
-
Seville, Spania
- Hs0005 40049
-
Valencia, Spania
- Hs0005 40230
-
-
-
-
-
Leeds, Storbritannia
- Hs0005 40339
-
-
-
-
-
Geneva, Sveits
- Hs0005 40406
-
-
-
-
-
Prague, Tsjekkia
- Hs0005 40063
-
Prague, Tsjekkia
- Hs0005 40194
-
-
-
-
-
Antalya, Tyrkia (Türkiye)
- Hs0005 40270
-
Gaziantep, Tyrkia (Türkiye)
- Hs0005 40273
-
Istanbul, Tyrkia (Türkiye)
- Hs0005 40272
-
Izmir, Tyrkia (Türkiye)
- Hs0005 40271
-
-
-
-
-
Berlin, Tyskland
- Hs0005 40325
-
Berlin, Tyskland
- Hs0005 40326
-
Bochum, Tyskland
- Hs0005 40248
-
Bonn, Tyskland
- Hs0005 40327
-
Darmstadt, Tyskland
- Hs0005 40288
-
Dresden, Tyskland
- Hs0005 40324
-
Dresden, Tyskland
- Hs0005 40356
-
Frankfurt am Main, Tyskland
- Hs0005 40287
-
Hamburg, Tyskland
- Hs0005 40142
-
Hanover, Tyskland
- Hs0005 40328
-
Kiel, Tyskland
- Hs0005 40249
-
Lübeck, Tyskland
- Hs0005 40250
-
Mainz, Tyskland
- Hs0005 40174
-
München, Tyskland
- Hs0005 40323
-
Münster, Tyskland
- Hs0005 40177
-
-
-
-
-
Debrecen, Ungarn
- Hs0005 40254
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Study participant has completed the Maintenance Treatment Period through Week 48 in HS0003 (NCT04242446) or HS0004 (NCT04242498), was eligible to receive bimekizumab at the time of completing the feeder study, and did not meet any withdrawal criteria of the feeder study
-
Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator
-
A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
- A WOCBP who agrees to follow the contraceptive guidance during the open-label extension period and for at least 20 weeks after the final dose of investigational medicinal product (IMP)
Exclusion Criteria:
- Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)
- Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments Note: For any study participant with an ongoing serious adverse event (SAE) from HS0003 (NCT04242446) or HS0004 (NCT04242498), or any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry or a history of serious infections in HS0003 or HS0004, the Medical Monitor must be consulted prior to the study participant's entry into HS0005, although the decision on whether to enroll the participant remains with the Investigator.
- Study participant has a positive or indeterminate interferon-gamma release assay (IGRA) in a feeder study, unless appropriately evaluated and treated
- Study participant has ongoing or planned use of prohibited hidradenitis suppurativa (HS) or non-HS treatment
- Study participant plans to participate in another study of a medicinal product or device under investigation during this study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Bimekizumab dosing regimen 1
Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the open-label extension period. |
Subjects will receive bimekizumab at pre-specified time-points.
Andre navn:
|
|
Eksperimentell: Bimekizumab dosing regimen 2
Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the open-label extension period. |
Subjects will receive bimekizumab at pre-specified time-points.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
Tidsramme: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. |
From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of participants with treatment-emergent serious adverse events (SAEs) during the study
Tidsramme: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose:
|
From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
|
Percentage of participants with treatment-emergent adverse events (TEAEs) leading to withdrawal from the study
Tidsramme: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs leading to discontinuation of the study are reported. |
From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
|
|
Percentage of participants achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)
Tidsramme: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
HiSCR50 is defined as at least a 50 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
|
Percentage of participants achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)
Tidsramme: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
HiSCR75 is defined as at least a 75 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
|
Percentage of participants with Flare
Tidsramme: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
Flare is defined as a ≥25 % increase in abscess and inflammatory nodule (AN) count with an absolute increase in AN count of ≥2 relative to Baseline. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
|
Hidradenitis Suppurativa Symptom Questionnaire (HSSQ) Response for Worst Pain
Tidsramme: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
The 4 items on the HSSQ assess the study participant's perception of the core symptoms of HS experienced in the past 7 days - pain, smell or odor, drainage or oozing from HS lesions, and itch on an 11-point numeric rating scale with higher scores indicating higher symptom level. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
|
Absolute change from Baseline in Dermatology Life Quality Index (DLQI) Total Score
Tidsramme: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
The DLQI is a skin disease specific questionnaire aimed at the evaluation of how the disease affects participants health related quality of life (QOL). The DLQI total score ranges from 0 to 30 with higher scores indicating higher skin disease impact on QOL. Results will be presented individually per week listed under time points. |
Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: UCB Cares, 001 844 599 2273
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Skrzypczak T, Skrzypczak A, Matusiak L, Szepietowski JC. An evaluation of bimekizumab for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther. 2025 Aug;25(8):811-819. doi: 10.1080/14712598.2025.2522119. Epub 2025 Jun 21.
- Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. J Am Acad Dermatol. 2026 Mar;94(3):867-878. doi: 10.1016/j.jaad.2025.11.031. Epub 2025 Nov 15.
- Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA. Drugs Real World Outcomes. 2026 Jul 29. doi: 10.1007/s40801-026-00564-8. Online ahead of print.
- Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. J Eur Acad Dermatol Venereol. 2026 Jul 22. doi: 10.1111/jdv.70631. Online ahead of print. No abstract available.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HS0005
- 2020-004179-42 (EudraCT-nummer)
- U1111-1307-6132 (Annen identifikator: World Health Organization (WHO))
- 2024-511035-10 (Registeridentifikator: EU Clinical Trials)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD-delingstidsramme
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Tilgangskriterier for IPD-deling
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .